Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells (Q39083094)

8 September 2017

title

Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells (English)

1 reference

8 September 2017

Yuji Sato

1 reference

8 September 2017

Masakazu Yashiro

series ordinal

1 reference

8 September 2017

Nobuyuki Takakura

series ordinal

1 reference

8 September 2017

publication date

28 October 2013

1 reference

8 September 2017

1 reference

8 September 2017

volume

104

1 reference

8 September 2017

1 reference

8 September 2017

page(s)

1618-1625

1 reference

8 September 2017

cites work

Cancer statistics, 2013

1 reference

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.

21 January 2018

1 reference

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

21 January 2018

1 reference

Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.

21 January 2018

1 reference

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines

21 January 2018

1 reference

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

21 January 2018

1 reference

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours

21 January 2018

1 reference

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

21 January 2018

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

21 January 2018

1 reference

MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells

21 January 2018

1 reference

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

21 January 2018

1 reference

Binding of Neu Differentiation Factor with the Extracellular Domain of Her2 and Her3

21 January 2018

1 reference

Development of an autocrine neuregulin signaling loop with malignant transformation of human breast epithelial cells

21 January 2018

1 reference

Autocrine activation of ErbB2/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines

21 January 2018

1 reference

Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells

21 January 2018

1 reference

Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers

21 January 2018

1 reference

Heregulin-alpha and heregulin-beta expression is linked to a COX-2-PGE2 pathway in human gastric fibroblasts

21 January 2018

1 reference

Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells

21 January 2018

1 reference

Upregulation of cancer-associated myofibroblasts by TGF-β from scirrhous gastric carcinoma cells

21 January 2018

1 reference

c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function

21 January 2018

1 reference

Signaling networks assembled by oncogenic EGFR and c-Met

21 January 2018

1 reference

FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival

21 January 2018

1 reference

Tyrosine phosphorylation of PYK2 mediates heregulin-induced glioma invasion: novel heregulin/HER3-stimulated signaling pathway in glioma.

21 January 2018

1 reference

High expression of HER3 is associated with a decreased survival in gastric cancer.

21 January 2018

1 reference

Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function

21 January 2018

1 reference

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

21 January 2018

1 reference

CIN85 phosphorylation is essential for EGFR ubiquitination and sorting into multivesicular bodies

21 January 2018

1 reference

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

21 January 2018

1 reference

Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models

21 January 2018

1 reference

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

21 January 2018

1 reference

12 December 2020

Expression of heregulin alpha, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells

1 reference

12 December 2020

Comparative study on overexpression of HER2/neu and HER3 in gastric cancer

1 reference

12 December 2020

Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines.

1 reference

12 December 2020

Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer.

1 reference

12 December 2020

Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression

1 reference

12 December 2020

Identifiers

DOI

10.1111/CAS.12290

1 reference

8 September 2017

1 reference